That is correct rapimeds looked to be very promising over a year ago. However, for whatever reason it did not materialize. Candidly, if management didn't secure this wonderful compounding situation there would be nothing much to talk about. But the reality is compounding is doing far better than I personally ever imagined at a 36m run rate where the profit margins are 70% and we pay out 50% comish so essentially we net 20% which is huge for scrc. If rappimeds ever ships the 200k order and then gets a re-order I will get more positive on it. Right now the focus is on compounding and building PIMD which will be significant over several quarters imo.